TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Net Cash Provided by (Used in) Financing Activities USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was -$151 M, a 78.6% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Net Cash Provided by (Used in) Financing Activities for the twelve months ending March 31, 2024 was -$1.36 B, a 38.1% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$1.91 B, a 28.6% decline from 2022.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$1.49 B, a 31.5% increase from 2021.
  • Teva Pharmaceutical Industries Ltd annual Net Cash Provided by (Used in) Financing Activities for 2021 was -$2.17 B, a 15.2% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$1.36 B -$151 M +$555 M +78.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$1.91 B -$576 M +$136 M +19.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$2.05 B -$576 M -$137 M -31.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$1.91 B -$55 M +$283 M +83.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$2.2 B -$706 M -$708 M -35400% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$1.49 B -$712 M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$439 M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$338 M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $2 M +$495 M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 -$493 M +$207 M +29.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q1 2020 -$700 M -$511 M -270% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q1 2019 -$189 M +$1.9 B +91% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 -$2.09 B -$323 M -18.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q1 2017 -$1.77 B -$2.04 B -762% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q1 2016 $267 M +$174 M +187% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q1 2015 $93 M +$727 M Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q1 2014 -$634 M +$1.63 B +71.9% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q1 2013 -$2.26 B -$1.65 B -269% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q1 2012 -$613 M +$157 M +20.4% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q1 2011 -$770 M -$595 M -340% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q1 2010 -$175 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.